Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ: MDGL) is set to announce topline results from its Phase 3 MAESTRO-NASH study of resmetirom on December 19, 2022. The press release will be available at 7:00 am EST, followed by a conference call at 8:00 am EST. Resmetirom is an innovative oral therapy targeting nonalcoholic steatohepatitis (NASH), an area of high unmet medical need. Madrigal aims to address the underlying causes of NASH through its thyroid hormone receptor-selective approach.

Positive

• Announcement of topline results from Phase 3 MAESTRO-NASH study, potentially significant for market perception.
• Resmetirom targets a critical area in liver disease with high unmet medical need.

Negative

• None.

CONSHOHOCKEN, Pa., Dec. 18, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), plans to announce topline results from the Phase 3 MAESTRO-NASH study of resmetirom on Monday, December 19^th, 2022.

The schedule for the press release and conference call/webcast is as follows:

• MAESTRO-NASH Press Release:		December 19th, 2022 at 7:00 am EST
• MAESTRO-NAFLD-1 Conference Call:		December 19th, 2022 at 8:00 am EST

To access the live webcast of the call with slides please visit the Investors section of Madrigal’s website or click here. To access the call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. An archived webcast will be available on the Madrigal website after the event.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver. For more information, visit www.madrigalpharma.com.

Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

FAQ

What are the topline results expected from the MAESTRO-NASH study on December 19, 2022?

Madrigal Pharmaceuticals will announce the topline results from the Phase 3 MAESTRO-NASH study of resmetirom, which targets nonalcoholic steatohepatitis.

What time will the MAESTRO-NASH press release be available?

The press release will be available on December 19, 2022, at 7:00 am EST.

Where can I access the conference call for the MAESTRO-NASH study?

The conference call will be accessible via the Investors section of Madrigal's website or through the provided registration link.

What is resmetirom and its significance in the treatment of NASH?

Resmetirom is an oral thyroid hormone receptor-selective agonist designed to treat nonalcoholic steatohepatitis, addressing the disease's underlying causes.